Dexcom INC Form 4 insider transactions

Michael Jon Brown, EVP Chief Legal Compliance Officer at DexCom Inc., reported a transaction involving common stock on May 22, 2026.

Dexcom Inc. EVP and CFO Jereme M. Sylvain reported a transaction involving the withholding of shares for tax obligations and disclosed beneficial ownership details.

Sadie Stern, EVP Chief People & Culture Officer at DexCom Inc., reported a transaction involving common stock, with shares withheld for tax obligations.

Dexcom Executive Chair Kevin R. Sayer sold 26,759 shares of common stock for $72 per share under a pre-arranged 10b5-1 trading plan.

DexCom Inc. reports that EVP Michael Jon Brown sold 1,700 shares of common stock on May 15, 2026, as part of a pre-arranged 10b5-1 trading plan.

Director Bridgette P. Heller of Dexcom Inc. has sold 1,012 shares of common stock for $60.01 per share under a pre-arranged 10b5-1 trading plan.

DexCom director Nicholas Augustinos transferred 5,046 shares of common stock into a revocable trust.

Director Richard Alexander Collins transferred 5,074 shares of DexCom common stock into his revocable trust.

DexCom Director Mark G. Foletta transferred 5,731 shares of common stock from direct ownership to a family trust.

DexCom Director Steven R. Altman transferred 5,037 shares of common stock into his family trust.

DexCom Executive Vice President and Chief Legal Officer Michael Jon Brown sold 1,700 shares of common stock under a 10b5-1 trading plan.

DEXCOM's EVP and Chief Legal Officer, Michael Jon Brown, sold 1,700 shares of common stock for $64.85 per share under a pre-arranged 10b5-1 plan.

DexCom Inc. Director Albert Frederick Osterloh IV was granted 7,061 restricted stock units, vesting over three years.

Dexcom's President, CEO, and Director, Jacob Steven Leach, reported the vesting of performance-based restricted stock units and subsequent tax withholding, increasing his direct beneficial ownership.

Dexcom's EVP, Chief HR Officer Sadie Stern acquired 7,123 shares of common stock through the vesting of performance-based restricted stock units, while 2,656 shares were withheld for tax obligations.

DexCom's EVP and Chief Financial Officer, Jereme M. Sylvain, reported the vesting of performance-based restricted stock units and subsequent tax-related share withholding.

Dexcom's EVP and Chief Legal Officer, Michael Jon Brown, increased his direct ownership of common stock through the vesting of performance-based restricted stock units.

Dexcom Executive Chair Kevin R. Sayer reported the vesting of performance-based restricted stock units and subsequent tax withholding, increasing his direct beneficial ownership.

DexCom Director Richard Collins sold 2,906 shares of common stock for $59.05 per share under a pre-arranged 10b5-1 trading plan.

DexCom Director Bridgette P. Heller disposed of 1,012 shares of common stock for $58.07 per share, executed under a pre-arranged 10b5-1 trading plan.

Dexcom's President & COO, Jacob Steven Leach, acquired 18,200 shares of common stock for over $1 million through open market purchases.

DexCom Director Richard Alexander Collins sold 3,948 shares of common stock for $55.17 per share, executed under a Rule 10b5-1 plan.

DexCom Director Euan A. Ashley received a grant of 7,166 restricted stock units, vesting in three equal annual installments.

DexCom Director Kyle Malady sold 667 shares of common stock for $80.86 per share on September 5, 2025, under a pre-arranged 10b5-1 trading plan.

DEXCOM's EVP, Chief HR Officer, Sadie Stern, sold 1,466 shares of common stock for $80 per share under a pre-arranged 10b5-1 plan.

Dexcom's EVP and Chief Financial Officer, Jereme M. Sylvain, sold 4,824 shares of common stock for $74.17 per share under a pre-arranged 10b5-1 trading plan.

Dexcom's EVP and Chief Legal Officer, Michael Jon Brown, sold 500 shares of common stock for $80.29 per share under a pre-arranged 10b5-1 trading plan.

Dexcom Director Mark G. Foletta sold 2,750 shares of common stock through a pre-arranged 10b5-1 trading plan.

Dexcom's EVP and Chief HR Officer, Sadie Stern, sold 1,466 shares of common stock for $88.99 per share under a Rule 10b5-1 trading plan.

DexCom Inc. Director Mark G. Foletta sold 2,750 shares of common stock through a pre-arranged 10b5-1 trading plan.